NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ARTBIO

ARTBIO

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://artbio.com/

Last Round

Series B

Jul 29, 2025

Total Funding Raised

$245M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ARTBIO is a biotechnology company that develops targeted alpha radioligand therapies for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

alpha-radioligand therapyARTradiopharmaceuticalsPb-212targeted cancer therapyprostate cancer treatmentsolid tumor therapyisotope chemistryclinical-stage biotechradioisotope supply chaintheranosticsnuclear medicineCDMOtargeted alpha therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ARTBIO Comparables

Compare ARTBIO with similar companies based on industry and business-model similarity.

ARTBIO comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aktis Oncology
88%
Ratio Therapeutics Inc.
88%
Eli Lilly and Company
81%

ARTBIO Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 29, 2025
Series ADec 7, 2023
SeedJun 21, 2023

ARTBIO Investors

Notable investors and investment history

ARTBIO investors
InvestorRounds
Omega FundsSeries B, Series A, Seed
B Capital GroupSeries B
F-Prime CapitalSeries A, Seed
Alexandria Venture InvestmentsSeries B
F-Prime CapitalSeries B, Series A, Seed
RadforskSeed
Sofinnova InvestmentsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Lead program AB001 is in first-in-human trials.

  • Jul 29, 2025

    $132M round closed.

ARTBIO Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ARTBIO Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ARTBIO's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range73
Year Founded2021
Last FundingJul 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.